With pricing pressures climbing, Pfizer, Eli Lilly and other major drugmakers are looking to sell their products directly to patients. Analysts are skeptical that these efforts, including those ...
Stocktwits on MSN
‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios
Traders floated scenarios ranging from a $20 billion buyout to a potential partnership with UnitedHealth, reviving Viking’s ...
Pfizer Inc. (NYSE: PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating ...
The company's shares (LLY) climbed 2.3% Tuesday to end at $988.62 a share, after closing at a record high of $966.64 on Monday. The rally has pushed Lilly's market capitalization up to $934.6 billion, ...
Lower prices for 15 drugs, including Ozempic and Wegovy, are expected to be announced by the end of the month. The price ...
Sarah Hall is leaving her role as president of FCB Health New York. The 2025 MM+M Agency 100 honoree confirmed the personnel move in a statement to MM+M on Tuesday afternoon. “Sarah Hall has decided ...
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...
There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be ...
As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...
16hon MSN
Where Will Pfizer Be in 3 Years?
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...
Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback